A blood test for methylated BCAT1 and IKZF1 vs. a fecal immunochemical test for detection of colorectal neoplasia

Clinical and Translational Gastroenterology

Volumn 7, Issue 1, 2016, Pages E137-

  Symonds, Erin L ^a,b   Pedersen, Susanne K ^c   Baker, Rohan T ^c   Murray, David H ^c   Gaur, Snigdha ^c   Cole, Stephen R ^a,b   Gopalsamy, Geetha ^a   Mangira, Dileep ^a   LaPointe, Lawrence C ^c   Young, Graeme P ^a  

^a FLINDERS UNIVERSITY   (Australia)

^b REPATRIATION GENERAL HOSPITAL   (Australia)

^c Clinical Genomics Pty Ltd   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; TUMOR MARKER;

ADENOMA; ADULT; AGE; AGED; ARTICLE; BCAT1 GENE; CANCER DIAGNOSIS; CANCER SCREENING; CANCER STAGING; CLINICAL EVALUATION; CLINICAL FEATURE; COHORT ANALYSIS; COLONOSCOPY; COLORECTAL CANCER; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DNA METHYLATION; FALSE POSITIVE RESULT; FECES ANALYSIS; FEMALE; GENDER; HEMOGLOBIN BLOOD LEVEL; HUMAN; IKZF1 GENE; MALE; METHYLATION; MULTIPLEX REAL TIME POLYMERASE CHAIN REACTION; OCCULT BLOOD; OCCULT BLOOD TEST; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY;

EID: 85043629408     PISSN: 2155384X     EISSN: None     Source Type: Journal    
DOI: 10.1038/ctg.2015.67     Document Type: Article

References (53)

1. Elmunzer BJ, Hayward RA, Schoenfeld PS et al. Effect of flexible sigmoidoscopy-based screening on incidence and mortality of colorectal cancer: A systematic review and metaanalysis of randomized controlled trials. PLoS Med 2012; 9: e1001352.
2. Hardcastle JD, Thomas WM, Chamberlain J et al. Randomised, controlled trial of faecal occult blood screening for colorectal cancer. Results for first 107, 349 subjects. Lancet 1989; 1: 1160 1164.
3. Kronborg O, Fenger C, Olsen J et al. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996; 348: 1467 1471.
4. Mandel JS, Church TR, Bond JH et al. The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med 2000; 343: 1603 1607.
5. Allison JE, Sakoda LC, Levin TR et al. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics. J Natl Cancer Inst 2007; 99: 1462 1470.
6. Garborg K, Holme O, Loberg M et al. Current status of screening for colorectal cancer. Ann Oncol 2013; 24: 1963 1972.
7. Halloran SP, Launoy G, Zappa M et al. European guidelines for quality assurance in colorectal cancer screening and diagnosis First Edition Faecal occult blood testing. Endoscopy 2012; 44 (Suppl 3): SE65 SE87.
8. Lansdorp-Vogelaar I, van Ballegooijen M, Boer R et al. A novel hypothesis on the sensitivity of the fecal occult blood test: results of a joint analysis of 3 randomized controlled trials. Cancer 2009; 115: 2410 2419.
9. Levi Z, Birkenfeld S, Vilkin A et al. A higher detection rate for colorectal cancer and advanced adenomatous polyp for screening with immunochemical fecal occult blood test than guaiac fecal occult blood test, despite lower compliance rate. A prospective, controlled, feasibility study. Int J Cancer 2011; 128: 2415 2424.
10. Park DI, Ryu S, Kim YH et al. Comparison of guaiac-based and quantitative immunochemical fecal occult blood testing in a population at average risk undergoing colorectal cancer screening. Am J Gastroenterol 2010; 105: 2017 2025.
11. Smith A, Young GP, Cole SR et al. Comparison of a brush-sampling fecal immunochemical test for hemoglobin with a sensitive guaiac-based fecal occult blood test in detection of colorectal neoplasia. Cancer 2006; 107: 2152 2159.
12. Steele RJ, McDonald PJ, Digby J et al. Clinical outcomes using a faecal immunochemical test for haemoglobin as a first-line test in a national programme constrained by colonoscopy capacity. United European Gastroenterol J 2013; 1: 198 205.
13. Young GP, Symonds EL, Allison JE et al. Advances in fecal occult blood tests: The FIT revolution. Dig Dis Sci 2015;60:609 622.
14. Rabeneck L, Rumble RB, Thompson F et al. Fecal immunochemical tests compared with guaiac fecal occult blood tests for population-based colorectal cancer screening. Can J Gastroenterol 2012; 26: 131 147.
15. Yamada T, Alpers D, Owyang C. Textbook of Gastroenterology, 5th edn, Lippincott Williams and Wilkins: Philadelphia, PA, USA, 2009.
16. Young GP. Screening for colorectal cancer-new evidence in the last 10 years. Cancer Forum 2014; 38: 11 14.
17. Cole SR, Gregory T, Whibley A et al. Predictors of re-participation in faecal occult blood testbased screening for colorectal cancer. Asian Pac J Cancer Prev 2012; 13: 5989 5994.
18. Gregory T, Cole SR, Wilson CJ et al. Exploring the validity of the continuum of resistance model for discriminating early from late and non-uptake of colorectal cancer screening: implications for the design of invitation and reminder letters. Int J Behav Med 2013; 20: 572 581.
19. Potter MB. Strategies and resources to address colorectal cancer screening rates and disparities in the United States and globally. Annu Rev Public Health 2013; 34: 413 429.
20. Quintero E, Castells A, Bujanda L et al. Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. N Engl J Med 2012; 366: 697 706.
21. AIHW. National Bowel Cancer Screening Program monitoring report: 2012 13. Australian Institute of Health and Welfare Canberra: Canberra, Australia, 2014.
22. Cole SR, Young GP, Esterman A et al. A randomised trial of the impact of new faecal haemoglobin test technologies on population participation in screening for colorectal cancer. J Med Screen 2003; 10: 117 122.
23. Cole SR, Zajac I, Gregory T et al. Psychosocial variables associated with colorectal cancer screening in South Australia. Int J Behav Med 2011; 18: 302 309.
24. Adler A, Geiger S, Keil A et al. Improving compliance to colorectal cancer screening using blood and stool based tests in patients refusing screening colonoscopy in Germany. BMC Gastroenterol 2014; 14: 183.
25. Osborne J, Wilson C, Moore V et al. Sample preference for colorectal cancer screening tests: blood or stool? OJPM 2012; 2: 326 331.
26. Church TR, Wandell M, Lofton-Day C et al. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut 2014; 63: 317 325.
27. Imperiale TF, Ransohoff DF, Itzkowitz SH et al. Multitarget stool DNA testing for colorectalcancer screening. N Engl J Med 2014; 370: 1287 1297.
28. Mitchell SM, Ross JP, Drew HR et al. A panel of genes methylated with high frequency in colorectal cancer. BMC Cancer 2014; 14: 54.
29. Pedersen S, Symonds E, Baker R et al. Evaluation of an assay for methylated BCAT1 and IKZF1 in plasma for detection of colorectal neoplasia. BMC Cancer 2015; 15: 654.
30. Pedersen SK, Baker RT, McEvoy A et al. A two-gene blood test for methylated DNA sensitive for colorectal cancer. PLoS One 2015; 10: e0125041.
31. Javierre BM, Rodriguez-Ubreva J, Al-Shahrour F et al. Long-range epigenetic silencing associates with deregulation of Ikaros targets in colorectal cancer cells. Mol Cancer Res 2011; 9: 1139 1151.
32. Kibriya MG, Raza M, Jasmine F et al. A genome-wide DNA methylation study in colorectal carcinoma. BMC Med Genomics 2011; 4: 50.
33. Schjerven H, McLaughlin J, Arenzana TL et al. Selective regulation of lymphopoiesis and leukemogenesis by individual zinc fingers of Ikaros. Nat Immunol 2013; 14: 1073 1083.
34. Tonjes M, Barbus S, Park YJ et al. BCAT1 promotes cell proliferation through amino acid catabolism in gliomas carrying wild-Type IDH1. Nat Med 2013; 19: 901 908.
35. Vincent A, Omura N, Hong SM et al. Genome-wide analysis of promoter methylation associated with gene expression profile in pancreatic adenocarcinoma. Clin Cancer Res 2011; 17: 4341 4354.
36. Yoshikawa R, Yanagi H, Shen CS et al. ECA39 is a novel distant metastasis-related biomarker in colorectal cancer. World J Gastroenterol 2006; 12: 5884 5889.
37. Zhang Z, Xu Z, Wang X et al. Ectopic Ikaros expression positively correlates with lung cancer progression. Anat Rec (Hoboken) 2013; 296: 907 913.
38. Johnson DA, Barclay RL, Mergener K et al. Plasma septin9 versus fecal immunochemical testing for colorectal cancer screening: A prospective multicenter study. PLoS One 2014; 9: e98238.
39. Benton SC, Seaman HE, Halloran SP. Faecal occult blood testing for colorectal cancer screening: The past or the future. Curr Gastroenterol Rep 2015; 17: 428.
40. Fraser CG, Allison JE, Young GP et al. A standard for Faecal Immunochemical TesTs for haemoglobin evaluation reporting (FITTER). Ann Clin Biochem 2014; 51: 301 302.
41. Edge SB, Compton CC. The American Joint Committee on Cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010; 17: 1471 1474.
42. Whitlock EP, Lin JS, Liles E et al. Screening for colorectal cancer: A targeted, updated systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2008; 149: 638 658.
43. Lane JM, Chow E, Young GP et al. Interval fecal immunochemical testing in a colonoscopic surveillance program speeds detection of colorectal neoplasia. Gastroenterology 2010; 139: 1918 1926.
44. Haug U, Knudsen AB, Lansdorp-Vogelaar I et al. Development of new non-invasive tests for colorectal cancer screening: The relevance of information on adenoma detection. Int J Cancer 2015; 136: 2864 2874.
45. Betge J, Pollheimer MJ, Lindtner RA et al. Intramural and extramural vascular invasion in colorectal cancer: prognostic significance and quality of pathology reporting. Cancer 2012; 118: 628 638.
46. Payne SR. From discovery to the clinic: The novel DNA methylation biomarker (m)SEPT9 for the detection of colorectal cancer in blood. Epigenomics 2010; 2: 575 585.
47. Chiu HM, Lee YC, Tu CH et al. Association between early stage colon neoplasms and falsenegative results from the fecal immunochemical test. Clin Gastroenterol Hepatol 2013; 11: 832 838.
48. Denters MJ, Deutekom M, Bossuyt PM et al. Lower risk of advanced neoplasia among patients with a previous negative result from a fecal test for colorectal cancer. Gastroenterology 2012; 142: 497 504.
49. van Roon AH, Goede SL, van Ballegooijen M et al. Random comparison of repeated faecal immunochemical testing at different intervals for population-based colorectal cancer screening. Gut 2013; 62: 409 415.
50. Symonds EL, Young GP. Blood tests for colorectal cancer screening in the standard risk population. Curr Colorec Cancer Rep 2015, 10.1007/s11888-015-0293-2.
51. Zhou W, Feng X, Ren C et al. Over-expression of BCAT1, a c-Myc target gene, induces cell proliferation, migration and invasion in nasopharyngeal carcinoma. Mol Cancer 2013; 12: 53.
52. Connolly D, Hoang HG, Adler E et al. Septin 9 amplification and isoform-specific expression in peritumoral and tumor breast tissue. Biol Chem 2014; 395: 157 167.
53. Benning TM, Dellaert BG, Dirksen CD et al. Preferences for potential innovations in non-invasive colorectal cancer screening: A labeled discrete choice experiment for a Dutch screening campaign. Acta Oncol 2014; 53: 898 908.